Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 

Shots: Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate PharmaShots is pleased to feature Paul Howe, Chief Operations…
September 17, 2025

Read more

INSIGHTS+

New Drug Designations: June 2025 

Shots:     PharmaShots’ Designation Report offers a concise overview of the latest drug and device designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada, and NMPA  The June 2025 edition covers designations awarded to 43 drugs and 3 medical devices, comprising 17 small molecules, 7 biologics, 8 cell and gene therapies, and…
July 29, 2025

Read more

FDA Drug Approvals May 2025
INSIGHTS+

The US FDA New Drug Approvals in May 2025

Shots:     PharmaShots has compiled a list of US FDA-approved drugs in the month of May 2025      The US FDA has approved a total of 3 new drugs, including 2 new molecular entities and 1 Biologic leading to the treatment of patients and advances in the healthcare industry       The major highlighted drug was AbbVie’s Emrelis securing…
June 10, 2025

Read more

INSIGHTS+

New Drug Designations – April 2025  

Shots:    PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, Health Canada and NMPA  The April 2025 report covers designations granted to 36 drugs and 6 medical devices, spanning 14 small molecules, 3 biologics, 11 cell and gene therapies & 6 medical devices among…
May 27, 2025

Read more

Insight+_Ridhi Rastogi
INSIGHTS+

New Drug Designations – March 2025 

Shots:     PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA   The March 2025 report covers designations granted to 37 drugs and 3 medical devices, spanning 11 small molecules, 10 biologics, 10 cell and gene therapies & 3 medical devices among…
April 29, 2025

Read more

New Drug Designations - February 2025
INSIGHTS+

New Drug Designations – February 2025

Shots:    PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA  The February 2025 report covers designations granted to 53 drugs and 4 medical devices, spanning 16 small molecules, 14 biologics, 18 cell and gene therapies & 4 medical devices among…
March 25, 2025

Read more

New Drug Designations - January 2025
INSIGHTS+

New Drug Designations – January 2025

Shots:   PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA The January 2025 report covers designations granted to 53 drugs and 9 medical devices, spanning 18 small molecules, 13 biologics, 13 cell and gene therapies & 9 medical devices among…
February 28, 2025

Read more

New Drug Designations - December 2024
INSIGHTS+

New Drug Designations – December 2024

Shots:  PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA  The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others Significant…
January 31, 2025

Read more

Load more